EMA Application withdrawn: Zinmyleo (trilaciclib dihydrochloride) — Pharmacosmos A/S

View source ↗

Summary

The EMA has withdrawn the application for Zinmyleo (trilaciclib dihydrochloride) by Pharmacosmos A/S for small cell lung carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Carcinoma

Drugs mentioned

• Zinmyleo (trilaciclib dihydrochloride)

Snippet

Status: Application withdrawn. Therapeutic area: Small Cell Lung Carcinoma. MAH: Pharmacosmos A/S